Lung Transplant Center, Department of Thoracic Surgery, Wuxi People's Hospital Affiliated to Nanjing Medical University, Wuxi, 214023, China.
Clin Rheumatol. 2021 Sep;40(9):3789-3795. doi: 10.1007/s10067-021-05704-9. Epub 2021 Mar 23.
Lung transplantation (LTx) is the most important treatment for end-stage lung diseases. However, the treatment of connective tissue disease-associated interstitial lung diseases (CTD-ILD) using LTx is still controversial especially for polymyositis/dermatomyositis-associated interstitial lung disease (PM/DM-ILD).
Patients diagnosed with idiopathic pulmonary fibrosis (IPF) (n=180) and CTD-ILD (n= 36) from 1 January 2015 to 31 December 2019 were recruited into the study. We set polymyositis/dermatomyositis (PM/DM) as a single subgroup, and all the patients underwent LTx at the Wuxi People's Hospital.
We found that patients with non-myositis connective tissue-related ILD (NM-CTLD) were younger (p=0.007) and had a higher percentage of females (p=0.000) than patients with IPF. PM/DM-ILD was associated with a higher incidence of primary graft dysfunction (PGD) (p=0.006) and a longer time in the intensive care unit (ICU) (p=0.000). The cumulative survival rates of patients with PM/DM-ILD were significantly lower than those with IPF (log rank, p=0.003). However, there were no significant differences when compared with the cumulative survival rates of patients with NM-CTLD and IPF (log rank, p=0.528). Age- and gender-adjusted Cox proportional hazard analyses indicated that post-LTx PGD (HR 1.498, 95% CI 1.227-1.828, p=0.000) and duration of ICU (HR 1.027, 95% CI 1.007-1.047, p=0.000) were the independent contributors of disease status to survival. Lung infection was the leading cause of post-LTx death in the groups, where the incidence was 65.3% (47/72) in IPF, 66.7% (8/12) in NM-CTLD, and 66.7% (4/6) in PM/DM-ILD.
This study found that patients with NM-CTLD had a similar survival outcome with IPF. However, patients with PM/DM-ILD-performed LTx had a lower survival rate than those with IPF. Key Points • Previous studies have shown that the myopathies associated ILD patients had similar post-LTx outcomes with IPF patients. However, our retrospective analysis indicated that patients with PM/DM-ILD-performed LTx had a lower survival rate than those with IPF. • Patients with NM-CTLD had a similar survival outcome with IPF. • We also found that PM/DM-ILD was associated with a higher incidence of PGD and a longer time in the ICU.
肺移植(LTx)是治疗终末期肺部疾病的最重要手段。然而,对于结缔组织病相关间质性肺病(CTD-ILD),尤其是多发性肌炎/皮肌炎相关间质性肺病(PM/DM-ILD),使用 LTx 进行治疗仍存在争议。
我们纳入了 2015 年 1 月 1 日至 2019 年 12 月 31 日期间被诊断为特发性肺纤维化(IPF)(n=180)和 CTD-ILD(n=36)的患者。我们将多发性肌炎/皮肌炎(PM/DM)作为一个亚组,所有患者均在无锡市人民医院接受 LTx。
我们发现,非肌炎相关结缔组织疾病相关间质性肺病(NM-CTLD)患者比 IPF 患者更年轻(p=0.007),女性比例更高(p=0.000)。PM/DM-ILD 与原发性移植物功能障碍(PGD)发生率更高(p=0.006)和重症监护病房(ICU)时间更长(p=0.000)相关。PM/DM-ILD 患者的累积生存率明显低于 IPF 患者(log rank,p=0.003)。然而,与 NM-CTLD 和 IPF 患者的累积生存率相比,并无显著差异(log rank,p=0.528)。年龄和性别调整的 Cox 比例风险分析表明,LTx 后 PGD(HR 1.498,95%CI 1.227-1.828,p=0.000)和 ICU 持续时间(HR 1.027,95%CI 1.007-1.047,p=0.000)是影响生存状况的独立因素。肺部感染是各组患者 LTx 后死亡的主要原因,在 IPF 中发生率为 65.3%(47/72),NM-CTLD 为 66.7%(8/12),PM/DM-ILD 为 66.7%(4/6)。
本研究发现,NM-CTLD 患者的生存结局与 IPF 相似。然而,PM/DM-ILD 患者行 LTx 的生存率低于 IPF 患者。
先前的研究表明,与肌病相关的间质性肺病患者与 IPF 患者的 LTx 后结局相似。然而,我们的回顾性分析表明,PM/DM-ILD 患者行 LTx 的生存率低于 IPF 患者。
NM-CTLD 患者的生存结局与 IPF 相似。
我们还发现,PM/DM-ILD 与 PGD 发生率更高和 ICU 时间更长相关。